MetaVia Inc. (MTVA)vsRoyalty Pharma Plc (RPRX)
MTVA
MetaVia Inc.
$1.58
-1.11%
HEALTHCARE · Cap: $7.64M
RPRX
Royalty Pharma Plc
$57.80
+1.55%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
MTVA
Avoid26
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MTVA.
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$57.80
$23.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MTVA
The strongest argument for MTVA centers on Price/Book, Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
MTVA profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
MTVA carries more volatility with a beta of 0.97 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 26/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is a forward-thinking technology firm specializing in transformative digital solutions that optimize connectivity and productivity across various sectors. By harnessing state-of-the-art artificial intelligence and cloud computing, MetaVia develops robust, customized platforms designed to address the unique challenges of its clientele. With a strong commitment to sustainability and social responsibility, the company not only meets current market expectations but also fosters long-term growth potential. Positioned strategically to capitalize on evolving trends in the tech industry, MetaVia aims to deliver substantial value to its shareholders while adapting to an ever-changing landscape.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?